Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients

NCT06179888 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06179888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06179888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Suspended
Start date
August 27, 2024
Completion date
October 31, 2027
Enrollment
84 (estimated)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma